en · de · es · fr · pt
melanotan-2-notes.peptides6823.com › Blog › Identity And Chemical Background — Field Notes

Identity And Chemical Background — Field Notes

By Editorial Desk · published 2025-10-19 · last reviewed 2025-11-05 · Blog

This is a working overview of melanogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Regulation, Literature and Verification

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms differ
Molecular weightApproximately 1024 g/molCalculated for the free base
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and polar solventsPoorly soluble in non-polar solvents
Typical storage-20 degrees Celsius, dry, protected from lightRefers to the solid form

Melanotan II Background and Mechanism

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Related pages on this site

Storage, Stability, and Analysis

Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.

Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.

Chemistry and Receptor Pharmacology

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Quality Control and Analytical Practice

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.

Reference notes

Commissioned in June 1900, the French steam and electric Narval employed the now typical double-hull design, with a pressure hull inside the outer shell. These 200-ton ships had a range of over 160 km (100 mi) underwater. The French submarine Aigrette in 1904 further improved the concept by using a diesel rather than a gasoline engine for surface power. Large numbers of these submarines were built, with seventy-six completed before 1914. The Royal Navy commissioned five Holland-class submarines from Vickers, Barrow-in-Furness, under licence from the Holland Torpedo Boat Company from 1901 to 1903. Construction of the boats took longer than anticipated, with the first only ready for a diving trial at sea on 6 April 1902. Although the design had been purchased entirely from the US company, the actual design used was an untested improvement to the original Holland design using a new 180 horsepower (130 kW) petrol engine.

When the mixed sulfates were pure enough, they were once more converted to mixed chlorides; barium and radium thereafter were separated by fractional crystallisation while monitoring the progress using a spectroscope (radium gives characteristic red lines in contrast to the green barium lines), and the electroscope. After the isolation of radium by Marie and Pierre Curie from uranium ore from Jáchymov, several scientists started to isolate radium in small quantities. Later, small companies purchased mine tailings from Jáchymov mines and started isolating radium. In 1904, the Austrian government nationalised the mines and stopped exporting raw ore. Until 1912, when radium production increased, radium availability was low. The formation of an Austrian monopoly and the strong urge of other countries to have access to radium led to a worldwide search for uranium ores. The United States took over as leading producer in the early 1910s, producing 70 g total from 1913 to 1920 in Pittsburgh alone. The Curies' process was still used for industrial radium extraction in 1940, but mixed bromides were then used for the fractionation. If the barium content of the uranium ore is not high enough, additional barium can be added to carry the radium. These processes were applied to high grade uranium ores but may not have worked well with low grade ores. Small amounts of radium were still extracted from uranium ore by this method of mixed precipitation and ion exchange as late as the 1990s, but as of 2011, it is extracted only from spent nuclear fuel.

== Effects of nutritional status == The observations that long-term feed restriction does not significantly affect lep expression in Atlantic salmon has also been noted in other teleosts. However it is likely that prolonged feed restriction can influence several endocrine parameters to adapt to the nutritional condition. For example, in common carp, a rapid response in ob gene expression in hepatic tissue of common carp shortly after feeding, but no changes in expression in response to different long-term feeding regime was observed. These authors suggested that this effect could be explained by the fact that starved fish do not lose weight as rapidly as mammals, a consequence of being ectothermic and possessing a much lower standard metabolic rate, and therefore can withstand longer periods of starvation. A similar study on grass carp showed that chronic injection of species-specific Lep did not affect long-term food intake and body weight, while acute injection decreased food intake. Conversely, Murashita et al., (unpublished results) observed increased proopiomelanocortin a1(pomca1) levels following chronic injection of Lep in Atlantic salmon, which suggests that chronic exposure to elevated Lep levels can decrease food intake through the Pomc pathway in this species. Recent studies in Atlantic salmon did not observe any difference of feed restriction in circulating plasma levels, which contrasts recent results in rainbow trout and suggest that the relation between circulating lep levels and energy status differs from that in mammals.

=== Evermont: The Royal Rumble === First aired: 2 December 2010 Meet Evermont, a wannabe rapper who says he can "smell the bitch" in his victims. He calls himself "the king" and makes life miserable for Jesse and Colton. Mayhem Miller brings in professional MMA Brazilian jiu-jitsu fighter Bobby "King" Green who has a record of 14 wins and 3 losses to put Evermont in his place. In the first round, Bobby Green made him tap out five times. In the second round, Evermont got scared and didn't continue into the second round. He was the second bully to withdraw from the second round, the first being Emil. Jesse and Colton won $10,000.

Sources: en.wikipedia.org

Notes from published material

=== Snakes === Snakes that consume a diet largely composed of goldfish and feeder minnows are susceptible to developing thiamine deficiency. This is often a problem observed in captivity when keeping garter and ribbon snakes that are fed a goldfish-exclusive diet, as these fish contain thiaminase, an enzyme that breaks down thiamine.

=== Alanine === Alanine is produced by the transamination of one molecule of pyruvate using two alternate steps: 1) conversion of glutamate to α-ketoglutarate using a glutamate-alanine transaminase, and 2) conversion of valine to α-ketoisovalerate via Transaminase C. Not much is known about the regulation of alanine synthesis. The only definite method is the bacterium's ability to repress Transaminase C activity by either valine or leucine (see ilvEDA operon). Other than that, alanine biosynthesis does not seem to be regulated.

Iraqi ground forces consolidated their control of Kuwait City, then headed south and redeployed along the Saudi border. After the decisive Iraqi victory, Saddam initially installed a puppet regime known as the "Provisional Government of Free Kuwait" before installing his cousin Ali Hassan al-Majid as Kuwait's governor on 8 August.

== Taxonomy == The cabbage looper larva is a type of cabbage worm, a general term for a Lepidopteran pest that primarily feeds on crucifers. They closely resemble each other, in that they are all smooth and green, but they are not closely related in terms of phylogeny. In fact, none of the cabbage worms bear close phylogenetic relations, as they are all from different families. The cabbage looper is a member of the family Noctuidae, one of the largest families in Lepidoptera. It is related to other vegetable pests, like the cutworm and armyworms.

=== Provincial government === Yasir Naqvi, the Attorney General of Ontario, and Eric Hoskins, the province's Minister of Health and Long-Term Care, jointly announced on the day of Wettlaufer's sentencing that the provincial government would commission a public inquiry into her case. The full details of the inquiry were not given in the announcement, as the government had yet to determine the scope or an individual to lead the inquiry, with Naqvi and Hoskins instead saying that the inquiry would "get the answers we need to help ensure a tragedy such as this does not happen again." The delay in establishing the inquiry was criticized by members of the opposition Progressive Conservative and New Democratic parties toward the end of July 2017, as no progress had seemingly been made since the announcement and the Legislative Assembly had risen for its summer recess. The Public Inquiry into the Safety and Security of Residents in the Long-Term Care Homes System was formally established by the provincial government on August 1, 2017. Justice Eileen Gillese of the Court of Appeal for Ontario was appointed commissioner of the inquiry. The inquiry was to include interviews with victims' families and public consultations in the community as it investigated the circumstances surrounding the deaths of Wettlaufer's victims and gaps in legislative or policy frameworks that allowed her to continue working as a nurse. The inquiry's lead counsel stated that "anyone from Wettlaufer to Premier Kathleen Wynne" may be called to testify before the inquiry based on the evidence that is uncovered.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

How is melanotan-2 distinguished from afamelanotide?

Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.

Why does the compound appear in tanning-related discussion?

Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network